Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case Series
Authors:
- 1 October 2017
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 153 (4) , 1165-1166
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infectionHepatology, 2016
- Real‐world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment‐naive, genotype 1 hepatitis C‐infected patientsHepatology, 2016
- Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral TherapyClinical Infectious Diseases, 2015
- Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A InhibitorsGastroenterology, 2014
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without CirrhosisNew England Journal of Medicine, 2014
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinNew England Journal of Medicine, 2014
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014